Because the maturation process of CFTR can be strongly affected by class-2 CF mutations, we studied the effect of the FDA-approved corrector VX-809 (Hudock and Clancy, 2017) on the W361R-CFTR variant, by western blot and patch clamp (Figure 4). Here, CFTR is linked to cystic fibrosis.